Due diligence on a pharmacy

Due diligence on a pharmacy has to verify two things a set of financial statements will not show on its own: whether the script volume behind the revenue is stable and diversified, and whether the agreements the pharmacy depends on — banner, wholesaler, institutional supply — will actually assign to you on a change of ownership. Both questions determine whether the business you are buying keeps operating the way it has, and both are worth resolving before your conditional period expires rather than assumed.

Script volume and payer-mix verification

Request dispensing data broken out by payer — public drug plan, private insurance, cash pay — and by referring physician or clinic, over at least the past two to three years, rather than relying on a single aggregate script count. Concentration in a small number of physician relationships or a single institutional source is a materially different risk than volume spread across a broad patient base, even where the current total looks the same. Watch the trend line as closely as the current level: a script count that has been declining, even gradually, tells a different story than a stable or growing one and should shape how you price the deal. Recasting earnings for a pharmacy also means separating dispensing margin from front-store retail margin, since the two behave differently and a buyer’s advisor will want to see them broken apart rather than blended into a single revenue line.

The banner and wholesaler agreements — read the assignment clause first

Almost every banner, franchise and wholesaler agreement requires the counterparty’s consent before it can be assigned to a new owner, and that consent is not automatic. Request the actual agreements early in diligence, not a summary of their terms, and confirm directly with the banner or wholesaler what their approval process requires and how long it typically takes — this is frequently the longest step in a pharmacy sale’s timeline, and building your closing date around an optimistic guess rather than the counterparty’s actual answer is a common source of delay.

Controlled-substance inventory and licensing

Controlled-substance and narcotic dispensing sits under federal requirements layered on top of provincial pharmacy regulation, and the licence covering that inventory generally has its own transfer or re-issuance process separate from the pharmacy premises accreditation itself. Have the current controlled-substance inventory reconciled and counted as part of diligence, since discrepancies here are a compliance issue for the seller today and a potential inherited problem for you if they are not resolved before closing. Confirm early how long the controlled-substance licensing process will take in your name, and treat that timeline as a hard input into your closing date rather than a detail to sort out afterward. A pharmacist stepping into ownership for the first time should not assume this process moves at the same pace as general dispensing registration — ask the college directly rather than relying on a general timeline someone else quotes you.

Institutional and long-term-care contracts

Where the pharmacy holds long-term-care or other institutional supply contracts, request the agreements themselves and confirm whether they are assignable on a change of control or whether the institution has a separate approval or re-tendering process. A contract that terminates automatically on a change of ownership, or one the institution can decline to assign, can remove a meaningful share of dispensing volume overnight, and that risk needs to be priced into the deal or resolved as a closing condition rather than discovered afterward.

Corporate, college-standing and lien searches

Confirm the pharmacy’s accreditation standing with the provincial pharmacy college, along with the individual pharmacist’s registration status if you are relying on them staying on, and check for any active discipline or compliance history tied to the location. Run a corporate search on the pharmacy’s operating entity and a lien and execution search to confirm there are no undisclosed claims against the business or its inventory, and confirm the status of any lease and the landlord’s consent requirements in parallel, since a slow landlord can hold up an otherwise-ready closing.

Findings that should stop or reprice the deal

Four findings are worth treating as serious rather than routine: the banner or wholesaler signals it will not consent to assignment on acceptable terms; you cannot meet the province’s pharmacist-ownership threshold without a restructuring you had not planned for; a material long-term-care or institutional contract turns out not to be assignable; or controlled-substance licensing cannot realistically be transferred or re-issued before your target closing date. Any of these is grounds to renegotiate price, extend the timeline, restructure the deal, or walk away — surfacing them during diligence, rather than discovering them after closing, is the entire purpose of this stage.